Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

See http://www.merus.nl/technology/ for more information. Our Head Quarters are located in Utrecht, The Netherlands with an office in the US and collaborators around the world. Since 2017 we are NASDAQ listed. For more information, please visit http://www.merus.nl/. 

Merus is always on the lookout for experienced scientists, researchers, technicians and projectleaders for our Early Discovery, PreClinical, Biomarker and Antibody Discovery teams. Located in the heart of the Netherlands, we are closing in on cancer using bispecific antibodies.

Join our fight. Take on our challenge - and let’s fight cancer together.

Are you interested in working with us but you cannot find a suitable position online? Then please send us an e-mail at vacancies@merus.nl.

Meet Merus - Closing in on Cancer